Synthesis and Anti-Cancer Activity of New Pyrazolinyl-Indole Derivatives: Pharmacophoric Interactions and Docking Studies for Identifying New EGFR Inhibitors
作者:Habibullah Khalilullah、Deepak K. Agarwal、Mohamed J. Ahsan、Surender S. Jadav、Hamdoon A. Mohammed、Masood Alam Khan、Salman A. A. Mohammed、Riaz Khan
DOI:10.3390/ijms23126548
日期:——
exhibited by the compounds HD02 [1-(5-(1-H-indol-3-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl)-2-phenylethanone], HD05 [1-(3-(4-chlorophenyl)-5-(1H-indol-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)-2-phenoxyethanone], and HD12 [(3-(4-chlorophenyl)-5-(1H-indol-3-yl)-4,5-dihydro-1H-pyrazol-1-yl)(pyridin-4-yl)methanone] against some of the 56 types of NCI-based cell lines in different panels. Compound HD05 showed
合成了新设计的一系列含有吲哚的吡唑类似物,吡唑啉吲哚,并根据1 H NMR 的光谱数据确认了它们的结构,13C NMR 和 HR-MS 分析。初步抗癌活性测试由美国国家癌症研究所 (NCI, USA) 进行。化合物 HD02、HD05 和 HD12 对九种基于癌症类型的细胞系组显示出显着的细胞毒活性,这些细胞系包括白血病、结肠癌、乳腺癌、黑色素瘤、肺癌、肾癌、前列腺癌、CNS 和卵巢癌细胞系。化合物 HD02 [1-(5-(1-H-indol-3-yl)-3-(p-tolyl)-4,5-dihydro-1H-pyrazol-1-yl) 表现出最高的细胞毒性作用-2-苯乙酮],HD05 [1-(3-(4-氯苯基)-5-(1H-吲哚-3-基)-4,5-二氢-1H-吡唑-1-基)-2-苯氧基乙酮] , 和 HD12 [(3-(4-chlorophenyl)-5-(1H-indol-3-yl)-4